 | Exhibit 99.1 | |||||||
BeiGene Reports First Quarter 2022 Financial Results
•Recorded product revenue of $261.6 million for the first quarter, representing a 146% increase from $106.1 million in the prior year period
•BRUKINSA product revenue increased 372% globally versus the first quarter of 2021, led by growth in U.S. and China
•New global clinical data support FDA and EMA filings under review, including ALPINE trial of BRUKINSA versus ibrutinib in chronic lymphocytic leukemia
•Positive interim analysis of RATIONALE-306 study of tislelizumab in combination with chemotherapy in esophageal squamous cell carcinoma showed statistically significant and clinically meaningful improvement in overall survival
•Held groundbreaking for flagship U.S. manufacturing and clinical R&D facility in Hopewell, N.J.
CAMBRIDGE, Mass., BASEL, Switzerland and BEIJING, China, May 5, 2022 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported financial results for the first quarter of 2022, recent business highlights, and anticipated upcoming milestones.
“I have never been more confident in BeiGene. We made terrific progress in the first quarter with our global commercial performance in the U.S., Europe, and in Asia, and we continue to build on our strategic competitive advantages, including breaking ground on our flagship U.S. manufacturing and clinical R&D campus at Princeton Innovation West in Hopewell, N.J.,” said John V. Oyler, Co-Founder, Chairman, and CEO at BeiGene. “BRUKINSA and tislelizumab continue to validate our ability to run global clinical trials and bring impactful medicines to cancer patients. We announced long-term follow up data from our Phase 3 head-to-head global ALPINE trial in relapsed/refractory CLL, where BRUKINSA demonstrated superiority in overall response rate versus ibrutinib as assessed by an Independent Review Committee and continued to show lower rates of atrial fibrillation and flutter. Our tislelizumab program with Novartis has also progressed with positive data from RATIONALE 306, our global trial in 1L advanced esophageal cancer. We are well positioned to advance our pipeline and expand our global capabilities to meet the needs of patients around the world.”
Julia Wang, Chief Financial Officer, commented, “During the first quarter we saw product revenue grow meaningfully across our commercial portfolio and geographies, led by internally developed medicines, and we expect continued momentum based on approvals secured to date and upcoming milestones. We are well positioned financially with our strong capital position and look forward to our multiple upcoming catalysts.”
First Quarter 2022 Financial Results
Cash, Cash Equivalents, Restricted Cash, and Short-Term Investments were $6.3 billion as of March 31, 2022, compared to $6.6 billion as of December 31, 2021.
•In the three months ended March 31, 2022, cash used in operating activities was $236.6 million, primarily due to our net loss of $434.3 million, offset by a decrease in our net operating assets and liabilities of $122.1 million and by non-cash charges of $75.6 million; capital expenditures were $45.1 million; and cash used in financing activities was $11.3 million.
Revenue for the three months ended March 31, 2022 was $306.6 million, compared to $605.9 million in the same period of 2021.
•Product revenue totaled $261.6 million for the three months ended March 31, 2022, compared to $106.1 million in the same period of 2021, including:
–Global sales of BRUKINSA of $104.3 million for the first quarter of 2022, compared to $22.1 million in the prior year period;
–Sales of tislelizumab in China of $87.6 million for the first quarter of 2022, compared to $48.9 million in the prior year period;
–Sales of Amgen in-licensed products in China of $29.9 million for the first quarter of 2022, compared to $14.5 million in the prior year period. Prior year period sales do not include sales of BLINCYTO® and KYPROLIS®, which were launched in China in August 2021 and January 2022, respectively; and
| Exhibit 99.1 | |||||||
–Sales of BMS in-licensed products in China of $27.2 million for the first quarter of 2022, compared to $20.3 million in the prior year period.
•Collaboration revenue for the three months ended March 31, 2022 was $45.1 million, resulting from partial recognition of the upfront payments from Novartis of $650.0 million related to the tislelizumab agreement and $300.0 million related to the ociperlimab agreement, which were entered into in the first quarter and fourth quarter of 2021, respectively. Collaboration revenue for the three months ended March 31, 2021 was $499.8 million, resulting from the recognition of revenue of a significant portion of the upfront payment from Novartis related to the tislelizumab agreement.
Expenses for the three months ended March 31, 2022 were $749.9 million, compared to $535.7 million in the same period of 2021.
•Cost of Sales for the three months ended March 31, 2022 were $65.2 million, compared to $32.7 million in the same period of 2021. Cost of sales increased primarily due to increased product sales of tislelizumab and BRUKINSA, as well as BLYNCYTO, which commenced in August 2021.
•R&D Expenses for the three months ended March 31, 2022 were $389.9 million, compared to $320.7 million in the same period of 2021. The increase in R&D expenses was primarily attributable to increases in headcount and costs related to investment in our discovery and development activities, including our continued efforts to internalize research and clinical development activities, partially offset by lower fees paid to external CROs on clinical trials for tislelizumab, as well as decreased expense related to upfront fees for in-process R&D. Upfront fees related to in-process R&D for in-licensed assets totaled nil and $8.5 million in the first quarters of 2022 and 2021, respectively. Employee share-based compensation expense also contributed to the overall increase in R&D expenses and was $30.9 million for the three months ended March 31, 2022, compared to $21.9 million for the same period of 2021.
•SG&A Expenses for the three months ended March 31, 2022 were $294.6 million, compared to $182.1 million in the same period of 2021. The increase in SG&A expenses was primarily attributable to increased headcount, largely related to the expansion of our commercial teams, higher professional service fees and higher external commercial expenses, including selling and marketing, market access studies and promotional activities. The overall increase in SG&A expenses was also attributable to higher SG&A-related share-based compensation expense, which was $34.7 million and $23.9 million for the first quarters of 2022 and 2021, respectively.
•Net Loss for the quarter ended March 31, 2022 was $434.3 million, compared to net income of $66.5 million in the prior year period, primarily due to lower collaboration revenue. For the quarter ended March 31, 2022, net loss per share was or $0.33 per share, and $4.24 per American Depositary Share (ADS). For the quarter ended March 31, 2021, basic and diluted earnings per share were $0.06 and $0.05, respectively, and basic and diluted earnings per ADS were $0.73 and $0.69, respectively.
Recent Business Highlights
Commercial Operations
•Product sales increased 146% in the first quarter of 2022 compared to the prior year period, primarily due to increased sales of our internally developed products and in-licensed products from Amgen;
•Global sales of BRUKINSA totaled $104.3 million in the first quarter, representing a 372% increase compared to the prior year period. U.S. sales of BRUKINSA totaled $67.9 million in the first quarter, representing growth of 570% compared to the prior year period, driven by expanded uptake across all approved indications — mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM) and marginal zone lymphoma (MZL). BRUKINSA sales in China totaled $33.5 million in the first quarter, representing growth of 180% compared to the prior year period, driven by a significant increase in all approved indications, including chronic lymphocytic leukemia (CLL);
•Sales of tislelizumab in China totaled $87.6 million in the first quarter, representing a 79% increase compared to the prior year period. In the first quarter, new patient demand from broader reimbursement in additional National Reimbursement Drug List (NRDL) approved indications continued to drive increased market penetration and market share for tislelizumab; and
•Completed transition and initiated marketing and promotion of five Novartis approved and nationally reimbursed oncology products in China's Broad Markets. These products include: TAFINLAR® (dabrafenib), MEKINIST® (trametinib), VOTRIENT® (pazopanib), AFINITOR® (everolimus), and ZYKADIA® (ceritinib).
| Exhibit 99.1 | |||||||
Development Programs
BRUKINSA® (zanubrutinib), a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to maximize BTK occupancy and minimize off-target effects, approved in 47 markets including the U.S., China, European Union (EU), Great Britain, Canada, Australia and South Korea in selected indications and under development for additional approvals globally. The global BRUKINSA development program includes nearly 4,000 subjects enrolled to-date in more than 25 countries and regions.
•Announced additional results from the Phase 3 study ALPINE (NCT03734016) showing BRUKINSA demonstrated superiority versus ibrutinib in overall response rate as assessed by an Independent Review Committee (IRC) in patients with relapsed/refractory (R/R) CLL or small lymphocytic lymphoma (SLL). BRUKINSA was generally well tolerated with safety results consistent with previous studies; and
•Initiated patient enrollment for the Phase 3 study of zanubrutinib (NCT05100862) plus rituximab versus lenalidomide plus rituximab in patients with R/R MZL.
Tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages; approved in China in eight indications and under development for additional approvals globally. The global tislelizumab clinical development program includes more than 9,000 subjects enrolled to-date in more than 35 countries and regions.
•Received approval in China for two new indications: advanced unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, and in second-line esophageal squamous cell carcinoma (ESCC);
•Announced acceptance by the European Medicines Agency (EMA) of marketing authorization applications for tislelizumab for the treatment of patients with advanced or metastatic ESCC after prior chemotherapy and for patients with non-small cell lung cancers (NSCLC) including: as a monotherapy for the treatment of locally advanced or metastatic NSCLC after prior chemotherapy in adults; in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of locally advanced or metastatic squamous NSCLC in adults; and in combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of locally advanced or metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations;
•Announced that the global Phase 3 RATIONALE 306 trial (NCT03783442) of tislelizumab in combination with chemotherapy met the primary endpoint of overall survival (OS) in patients with previously untreated advanced or metastatic ESCC at interim analysis;
•Presented updated results from the Phase 3 RATIONALE 309 trial (NCT03924986) of tislelizumab in first-line patients with nasopharyngeal cancer (NPC) at the Virtual American Society of Clinical Oncology (ASCO) Plenary Series, results will also be presented at the 2022 ASCO annual meeting;
•Presented clinical results and biomarker data on tislelizumab in solid tumors at the American Academy for Cancer Research (AACR) Annual Meeting, including the RATIONALE 303 (NCT03358875) and 304 (NCT03663205) Phase 3 studies evaluating tislelizumab in locally advanced or metastatic NSCLC; and
•Announced positive findings from interim analysis of the global Phase 3 RATIONALE 305 trial (NCT03777657) versus placebo in combination with chemotherapy as a first-line treatment for patients with locally advanced, unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with PD-L1 >5% expression. The study is continuing to final analysis.
Ociperlimab (BGB-A1217), an investigational anti-TIGIT monoclonal antibody with competent Fc function. The global ociperlimab development program includes more than 25 countries and regions, and more than 1,000 subjects have been enrolled.
•Entered strategic option, collaboration and license agreement with Novartis to develop, manufacture and commercialize ociperlimab in North America, Europe and Japan.
| Exhibit 99.1 | |||||||
Early-Stage Programs
•Continued to advance our early-stage clinical pipeline of internally-developed product candidates at dose escalation stage, including:
–BGB-A445: an investigational non-ligand competing OX40 monoclonal antibody as monotherapy or in combination with tislelizumab in solid tumors;
–BGB-15025: an investigational hematopoietic progenitor kinase 1 (HPK1) inhibitor as monotherapy or in combination with tislelizumab in solid tumors;
–BGB-10188: an investigational PI3Kδ inhibitor as monotherapy or in combination with BRUKINSA in hematology malignancies, or in combination with tislelizumab in solid tumors; and
–BGB-23339: a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor.
•Initiated patient dosing in the Phase 1 trial (NCT05006716) in patients with B-cell malignancies for BGB-16673 (an investigational Chimeric Degradation Activating Compound, or CDAC, targeting BTK).
Amgen Milestones
•Received conditional approval in China for BLINCYTO® (blinatumomab) for injection for the treatment of pediatric patients with R/R CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). This approval was based on ex-China research data and Chinese adult data and full approval in this indication will depend on the results of a post-marketing study in China; and
•In collaboration with Amgen, launched KYPROLIS® (carfilzomib) for injection, a next-generation proteasome inhibitor, in China for patients with R/R multiple myeloma.
Zymeworks Milestones
•In collaboration with Zymeworks, completed enrollment in the global HERIZON-BTC-01 pivotal clinical trial (NCT04466891) evaluating the anti-tumor activity of zanidatamab monotherapy in patients with previously treated advanced or metastatic HER2-amplified biliary tract cancers (BTC), including gallbladder cancer and cholangiocarcinoma (bile duct cancer).
Bio-Thera Milestones
•Received approval in China for POBEVCY® in three new indications, including for the treatment of adult patients with recurrent glioblastoma; as a combination therapy with carboplatin and paclitaxel for the first-line treatment of stage III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer after primary surgical resection; and as a combination therapy with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of persistent, recurrent or metastatic cervix carcinoma.
Manufacturing Operations
•Held a groundbreaking for our flagship U.S. commercial-stage manufacturing and clinical R&D campus at the Princeton West Innovation Campus in Hopewell, N.J. Construction of the initial phase is expected to commence in 2022. The property has more than one million square feet of developable real estate for potential future expansion;
•Construction has started on our new small molecule manufacturing campus in Suzhou, China. Phase 1 of construction is expected to bring more than 52,000 square meters and expand production capacity to 600 million tablets/capsules and be completed in 2023. Once completed, qualified, and approved, the total production capacity is expected to increase our small molecule manufacturing capability in China by up to a total of ten times capacity; and
•Continued construction on our state-of-the-art biologics facility in Guangzhou, China, which currently is approved for 8,000 liters of biologics capacity, with an additional phase of construction to bring total capacity to 64,000 liters expected to be completed and GMP-ready by the end of 2022.
Corporate Developments
•Engaged Ernst & Young LLP based in Boston, Mass., as the principal auditor for our financial statements and internal control over financial reporting for the fiscal year ending December 31, 2022 to be filed with the SEC; and
| Exhibit 99.1 | |||||||
•Published our 2021 Environmental, Social, and Governance (ESG) Report and introduced our Change Is The Cure™ global ESG strategy that will guide our efforts across five focus areas in which we plan to set goals and track progress. This strategy codifies the work we are doing to go beyond development of medicines to meet the needs of a global population and create a more equitable and sustainable world.
Expected Milestones
BRUKINSA
•Present clinical data from the global Phase 2 ROSEWOOD trial (NCT03332017) in R/R follicular lymphoma and long-term follow-up results from the Phase 3 ASPEN trial (NCT03053440) of zanubrutinib vs ibrutinib in patients with WM at the 2022 ASCO annual meeting;
•Continue to support ongoing FDA review of the supplemental new indication submission for CLL/SLL, which has a PDUFA target action date of October 22, 2022;
•Continue to support the EMA review of new indication applications for CLL and MZL;
•Announce final analysis data for the global Phase 3 ALPINE trial (NCT03734016) including progression-free survival in the second half of 2022; and
•Continue to expand BRUKINSA’s registration program globally in new geographies and indications, including potential launches in 2022 in more than 10 markets.
Tislelizumab
•Continue to support China NMPA review of BLA submission for tislelizumab as a first-line treatment for patients with recurrent or metastatic NPC;
•In collaboration with Novartis, continue to support the EMA review of MAAs for tislelizumab in first-line and second- and third-line NSCLC and second-line ESCC;
•Continue to support additional planned BLA filings by Novartis in first-line NPC in the U.S. and in NSCLC in the U.S. in 2022;
•In collaboration with Novartis, continue to support the ongoing FDA review of the BLA submission in second-line ESCC, with a target PDUFA date of July 12, 2022, subject to completion of regulatory inspections which may be delayed due to COVID-19 restrictions; and
•Announce topline results from the global Phase 3 clinical trial (NCT03412773) of tislelizumab as first-line treatment for patients with hepatocellular carcinoma (HCC) in 2022.
Ociperlimab
•Initiate additional pivotal clinical trials in 2022; and
•Announce data from Phase 1 trial (NCT04047862) cohorts in various solid tumor types in the second half of 2022.
Pamiparib
•Report topline results from the Phase 3 trial (NCT03519230) in China of pamiparib as a maintenance treatment in patients with platinum-sensitive recurrent ovarian cancer in 2022.
BGB-11417 (BCL-2)
•Initiate pivotal trials in the second half of 2022;
•Present Phase 1 clinical data for non-hodgkin lymphoma (NHL), acute myeloid leukemia and CLL (NCT04277637 and NCT04771130) at a medical congress in the second quarter of 2022; and
•Present additional Phase 1 data in late 2022.
| Exhibit 99.1 | |||||||
Early-Stage Programs
•Initiate dose expansion in the Phase 1 clinical trial (NCT04215978) of BGB-A445 (OX-40) in patients with advanced solid tumors in the first half of 2022;
•Initiate tumor specific expansions for BGB-15025, an investigational HPK1 inhibitor, in combination with tislelizumab in 2022; and
•In collaboration with Leads Biolabs, initiate patient dosing of LBL-007, a novel investigational antibody targeting the LAG-3 pathway in combination with tislelizumab and surzebiclimab (TIM3) in 2022.
Zanidatamab
•In collaboration with Zymeworks, announce efficacy and safety results from HERIZON-BTC-01 (NCT04466891) by early 2023.
COVID-19 Impact and Response
We expect that the worldwide health crisis of COVID-19 will continue to have a negative impact on our operations, including commercial sales, regulatory interactions, inspections, filings, manufacturing, and clinical trial recruitment, participation, and data read outs. There remains uncertainty regarding the future impact of the pandemic both globally and specifically in China due to outbreaks and restrictions and potential impact on clinical, manufacturing and commercial operations. We are striving to minimize delays and disruptions, have put protocols and procedures in place, and continue to execute on our commercial, regulatory, manufacturing, and clinical development goals globally.
| Exhibit 99.1 | |||||||
Financial Summary
Select Condensed Consolidated Balance Sheet Data (U.S. GAAP)
(Amounts in thousands of U.S. Dollars)
| As of | |||||||||||
| March 31, | December 31, | ||||||||||
| 2022 | 2021 | ||||||||||
| (unaudited) | (audited) | ||||||||||
| Assets: | |||||||||||
| Cash, cash equivalents, restricted cash and short-term investments | $ | 6,252,233 | $ | 6,624,849 | |||||||
| Accounts receivable, net | 190,800 | 483,113 | |||||||||
| Property and equipment, net | 624,673 | 587,605 | |||||||||
| Total assets | 8,021,388 | 8,645,949 | |||||||||
| Liabilities and equity: | |||||||||||
| Accounts payable | 236,915 | 262,400 | |||||||||
| Accrued expenses and other payables | 385,976 | 558,055 | |||||||||
| Deferred revenue | 368,027 | 407,703 | |||||||||
| R&D cost share liability | 368,543 | 390,362 | |||||||||
| Debt | 608,992 | 629,678 | |||||||||
| Total liabilities | 2,135,888 | 2,402,962 | |||||||||
| Total equity | $ | 5,885,500 | $ | 6,242,987 | |||||||
| Exhibit 99.1 | |||||||
Condensed Consolidated Statements of Operations (U.S. GAAP)
(Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs), per share and per ADS data)
| Three Months Ended March 31, | |||||||||||
| 2022 | 2021 | ||||||||||
| (Unaudited) | |||||||||||
| Revenue: | |||||||||||
| Product revenue, net | $ | 261,573 | $ | 106,117 | |||||||
| Collaboration revenue | 45,053 | 499,755 | |||||||||
| Total revenues | 306,626 | 605,872 | |||||||||
| Expenses: | |||||||||||
| Cost of sales - products | 65,237 | 32,685 | |||||||||
| Research and development | 389,915 | 320,726 | |||||||||
| Selling, general and administrative | 294,573 | 182,106 | |||||||||
| Amortization of intangible assets | 188 | 188 | |||||||||
| Total expenses | 749,913 | 535,705 | |||||||||
| (Loss) income from operations | (443,287) | 70,167 | |||||||||
| Interest income (expense), net | 10,071 | (4,179) | |||||||||
| Other income (loss), net | 11,967 | (4,123) | |||||||||
| (Loss) income before income taxes | (421,249) | 61,865 | |||||||||
| Income tax expense (benefit) | 13,025 | (4,630) | |||||||||
| Net (loss) income | (434,274) | 66,495 | |||||||||
| Net (loss) income per share attributable to BeiGene, Ltd.: | |||||||||||
| Basic | $ | (0.33) | $ | 0.06 | |||||||
| Diluted | $ | (0.33) | $ | 0.05 | |||||||
| Weighted-average shares outstanding: | |||||||||||
| Basic | 1,332,017,262 | 1,188,943,726 | |||||||||
| Diluted | 1,332,017,262 | 1,257,489,671 | |||||||||
| Net (loss) income per ADS attributable to BeiGene, Ltd. | |||||||||||
| Basic | $ | (4.24) | $ | 0.73 | |||||||
| Diluted | $ | (4.24) | $ | 0.69 | |||||||
| Weighted-average ADSs outstanding: | |||||||||||
| Basic | 102,462,866 | 91,457,210 | |||||||||
| Diluted | 102,462,866 | 96,729,975 | |||||||||
| Exhibit 99.1 | |||||||
About BeiGene
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 8,000 colleagues across five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding clinical data for BeiGene’s drug candidates and approvals of its medicines; the conduct of late-stage clinical trials and expected data readouts; additional planned product approvals and launches; the advancement of and anticipated clinical development, regulatory approvals and other milestones and commercialization of BeiGene’s medicines and drug candidates; the success of BeiGene’s commercialization efforts and revenue growth; the expected capacities and completion dates for the Company’s manufacturing facilities under construction; the impact of the COVID-19 pandemic on the Company’s clinical development, regulatory, commercial, manufacturing, and other operations; BeiGene’s plans and the expected events and milestones under the captions “Recent Business Highlights” and “Expected Milestones”; and BeiGene’s plans, commitments, aspirations and goals under the caption “About BeiGene”. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; the impact of the COVID-19 pandemic on BeiGene’s clinical development, regulatory, commercial, manufacturing, and other operations, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
| Investor Contact | Media Contact | |||||||
| Kevin Mannix | Emily Collins | |||||||
| +1 857-302-5189 | +1 201-201-4570 | |||||||
| ir@beigene.com | media@beigene.com | |||||||
BLINCYTO® and KYPROLIS® are registered trademarks of Amgen.
TAFINLAR®, MEKINIST®, VOTRIENT®, AFINITOR® and ZYKADIA® are registered trademarks of Novartis AG.
POBEVCY® is a registered trademark of Bio-Thera Solutions, Ltd.
